Neuroprotective therapies for Alzheimer's disease
Huber, Anke, Stuchbury, Grant, Bürkle, Alex, Burnell, Jim, and Münch, Gerald (2006) Neuroprotective therapies for Alzheimer's disease. Current Pharmaceutical Design, 12 (6). pp. 705-717.
|PDF (Published Version) - Repository staff only - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader|
View at Publisher Website: http://dx.doi.org/10.2174/13816120677547...
One of the major age-related damaging agents are reactive oxygen species (ROS). The brain is more vulnerable to oxidative stress than other organs as concomitant low activity and capacity of antioxidative protection systems allow for increased exposure of target molecules to ROS. Since neurons are postmitotic cells, they have to live with cellular damage accumulated over many decades. Increased levels of ROS (also termed "oxidative stress"), produced by normal mitochondrial activity, inflammation and excess glutamate levels, are proposed to accelerate neurodegenerative processes characteristic of Alzheimer's disease. This review presents evidence of the importance of oxidative stress in the pathogenesis of these diseases and explains the nature of different types of ROS mediating neuronal damage. Furthermore, the potential beneficial effects of neuroprotective treatments, including antioxidants and anti - glutamatergic drugs are discussed.
|Item Type:||Article (Refereed Research - C1)|
|Keywords:||Alzheimer's Disease; antioxidants; NMDA receptors|
|FoR Codes:||11 MEDICAL AND HEALTH SCIENCES > 1109 Neurosciences > 110999 Neurosciences not elsewhere classified @ 100%|
|SEO Codes:||92 HEALTH > 9201 Clinical Health (Organs, Diseases and Abnormal Conditions) > 920111 Nervous System and Disorders @ 100%|
|Deposited On:||24 Nov 2009 14:18|
|Last Modified:||18 Oct 2013 00:32|
Last 12 Months: 0
|Citation Counts with External Providers:|
Repository Staff Only: item control page